AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination

AbbVie said on Thursday its experimental drug significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the ​main goal of a late-stage study.